Published in Medical Device Law Weekly, April 25th, 2004
The patent, number U.S. 6,696,239, is granted for comparative phenotypic analysis for assessment of biological active compounds. This patent, along with other recently announced patents, extends the number of patents granted on the PM technology. The company now has more than 22 patents on its cellular assay technologies.
The PM technology has applications in multiple areas of research, ranging from basic research to high-throughput screening of chemical compounds against cells. Already working with a diverse list of microbial species including...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.